Loading
A phase 1/2 trial of Lenalidomide, Dexamethasone, Daratumumab in multiple myeloma, run by AbbVie, now recruiting.
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations is a phase 1/2 interventional study registered as NCT06892522 by AbbVie, with 602 participants planned, started 2025-06-30 and due to reach its primary completion in 2035-12. Interventions recorded: Etentamig, Lenalidomide, Dexamethasone, Daratumumab, Dexamethasone. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Iberdomide, Carfilzomib, Daratumumab, Dexamethasone.
Shares Carfilzomib, Daratumumab, Lenalidomide, Dexamethasone.
Shares Mezigdomide, Carfilzomib, Daratumumab, Dexamethasone.
Shares Daratumumab, AbbVie (incl. ImmunoGen, Capstan), Dexamethasone, Multiple myeloma.
Shares Daratumumab, AbbVie (incl. ImmunoGen, Capstan), Lenalidomide, Dexamethasone.
Shares Mezigdomide, Carfilzomib, Dexamethasone, Multiple myeloma.
Shares Iberdomide, Lenalidomide, Dexamethasone, Multiple myeloma.
Shares Daratumumab, Lenalidomide, Dexamethasone, Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/